Leptin Resistance. A Possible Interface of Inflammation and Metabolism in Obesity-Related Cardiovascular Disease

Journal of the American College of Cardiology

Volumn 52, Issue 15, 2008, Pages 1201-1210

  Martin, Seth S ^a   Qasim, Atif ^a   Reilly, Muredach P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

atherosclerosis; cardiovascular disease; inflammation; leptin resistance; obesity

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYTOKINE; INSULIN; INTERLEUKIN 18; INTERLEUKIN 6; LEPTIN; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ATHEROGENESIS; ATHEROSCLEROSIS; AUTOREGULATION; BLOOD LEVEL; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; ENERGY BALANCE; GENE MUTATION; HEART MUSCLE INJURY; HORMONAL REGULATION; HUMAN; HYPERLEPTINEMIA; HYPERTENSION; INFLAMMATION; INNATE IMMUNITY; INSULIN RESISTANCE; LIVER INJURY; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS INJURY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN LIPID INTERACTION; REVIEW; THROMBOCYTE; THROMBOSIS; TISSUE INJURY;

EID: 52949129178     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.05.060     Document Type: Review

References (133)

1. Friedman J.M., and Halaas J.L. Leptin and the regulation of body weight in mammals. Nature 395 (1998) 763-770
2. Ahima R.S., and Flier J.S. Leptin. Annu Rev Physiol 62 (2000) 413-437
3. Mantzoros C.S., Liolios A.D., Tritos N.A., et al. Circulating insulin concentrations, smoking, and alcohol intake are important independent predictors of leptin in young healthy men. Obes Res 6 (1998) 179-186
4. Soderberg S., Ahren B., Jansson J.H., et al. Leptin is associated with increased risk of myocardial infarction. J Intern Med 246 (1999) 409-418
5. Wallace A.M., McMahon A.D., Packard C.J., et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 104 (2001) 3052-3056
6. Wolk R., Berger P., Lennon R.J., Brilakis E.S., Johnson B.D., and Somers V.K. Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol 44 (2004) 1819-1824
7. Reilly M.P., Iqbal N., Schutta M., et al. Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. J Clin Endocrinol Metab 89 (2004) 3872-3878
8. Lam Q.L., and Lu L. Role of leptin in immunity. Cell Mol Immunol 4 (2007) 1-13
9. Chen K., Li F., Li J., et al. Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nat Med 12 (2006) 425-432
10. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352 (2005) 1685-1695
11. Ingalls A.M., Dickie M.M., and Snell G.D. Obese, a new mutation in the house mouse. J Hered 41 (1950) 317-318
12. Coleman D.L. Effects of parabiosis of obese with diabetes and normal mice. Diabetologia 9 (1973) 294-298
13. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., and Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 372 (1994) 425-432
14. Pelleymounter M.A., Cullen M.J., Baker M.B., et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 269 (1995) 540-543
15. Harigaya A., Nagashima K., Nako Y., and Morikawa A. Relationship between concentration of serum leptin and fetal growth. J Clin Endocrinol Metab 82 (1997) 3281-3284
16. Considine R.V., Sinha M.K., Heiman M.L., et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334 (1996) 292-295
17. Kennedy A., Gettys T.W., Watson P., et al. The metabolic significance of leptin in humans: gender-based differences in relationship to adiposity, insulin sensitivity, and energy expenditure. J Clin Endocrinol Metab 82 (1997) 1293-1300
18. Frederich R.C., Lollmann B., Hamann A., et al. Expression of ob mRNA and its encoded protein in rodents. Impact of nutrition and obesity. J Clin Invest 96 (1995) 1658-1663
19. Zhang F., Basinski M.B., Beals J.M., et al. Crystal structure of the obese protein leptin-E100. Nature 387 (1997) 206-209
20. Tilg H., and Moschen A.R. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6 (2006) 772-783
21. Margetic S., Gazzola C., Pegg G.G., and Hill R.A. Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord 26 (2002) 1407-1433
22. Tartaglia L.A., Dembski M., Weng X., et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 83 (1995) 1263-1271
23. Baumann H., Morella K.K., White D.W., et al. The full-length leptin receptor has signaling capabilities of interleukin 6-type cytokine receptors. Proc Natl Acad Sci U S A 93 (1996) 8374-8378
24. Lee G.H., Proenca R., Montez J.M., et al. Abnormal splicing of the leptin receptor in diabetic mice. Nature 379 (1996) 632-635
25. Bjorbaek C., Uotani S., da Silva B., and Flier J.S. Divergent signaling capacities of the long and short isoforms of the leptin receptor. J Biol Chem 272 (1997) 32686-32695
26. Lollmann B., Gruninger S., Stricker-Krongrad A., and Chiesi M. Detection and quantification of the leptin receptor splice variants Ob-Ra, b, and, e in different mouse tissues. Biochem Biophys Res Commun 238 (1997) 648-652
27. Bjorbaek C., El-Haschimi K., Frantz J.D., and Flier J.S. The role of SOCS-3 in leptin signaling and leptin resistance. J Biol Chem 274 (1999) 30059-30065
28. Schwartz M.W., Prigeon R.L., Kahn S.E., et al. Evidence that plasma leptin and insulin levels are associated with body adiposity via different mechanisms. Diabetes Care 20 (1997) 1476-1481
29. Heymsfield S.B., Greenberg A.S., Fujioka K., et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 282 (1999) 1568-1575
30. Chen H., Charlat O., Tartaglia L.A., et al. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 84 (1996) 491-495
31. Considine R.V., Considine E.L., Williams C.J., et al. Evidence against either a premature stop codon or the absence of obese gene mRNA in human obesity. J Clin Invest 95 (1995) 2986-2988
32. Zhang Y., and Scarpace P.J. The role of leptin in leptin resistance and obesity. Physiol Behav 88 (2006) 249-256
33. Scarpace P.J., Matheny M., and Tumer N. Hypothalamic leptin resistance is associated with impaired leptin signal transduction in aged obese rats. Neuroscience 104 (2001) 1111-1117
34. Wilsey J., and Scarpace P.J. Caloric restriction reverses the deficits in leptin receptor protein and leptin signaling capacity associated with diet-induced obesity: role of leptin in the regulation of hypothalamic long-form leptin receptor expression. J Endocrinol 181 (2004) 297-306
35. Wilsey J., Zolotukhin S., Prima V., Shek E.W., Matheny M.K., and Scarpace P.J. Hypothalamic delivery of doxycycline-inducible leptin gene allows for reversible transgene expression and physiological responses. Gene Ther 9 (2002) 1492-1499
36. Scarpace P.J., Matheny M., Zhang Y., et al. Central leptin gene delivery evokes persistent leptin signal transduction in young and aged-obese rats but physiological responses become attenuated over time in aged-obese rats. Neuropharmacology 42 (2002) 548-561
37. Scarpace P.J., Matheny M., Tumer N., Cheng K.Y., and Zhang Y. Leptin resistance exacerbates diet-induced obesity and is associated with diminished maximal leptin signalling capacity in rats. Diabetologia 48 (2005) 1075-1083
38. Bjorbaek C., Elmquist J.K., Michl P., et al. Expression of leptin receptor isoforms in rat brain microvessels. Endocrinology 139 (1998) 3485-3491
39. Banks W.A., Kastin A.J., Huang W., Jaspan J.B., and Maness L.M. Leptin enters the brain by a saturable system independent of insulin. Peptides 17 (1996) 305-311
40. Van Heek M., Compton D.S., France C.F., et al. Diet-induced obese mice develop peripheral, but not central, resistance to leptin. J Clin Invest 99 (1997) 385-390
41. Schwartz M.W., Peskind E., Raskind M., Boyko E.J., and Porte Jr. D. Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans. Nat Med 2 (1996) 589-593
42. Bjorbaek C., Elmquist J.K., Frantz J.D., Shoelson S.E., and Flier J.S. Identification of SOCS-3 as a potential mediator of central leptin resistance. Mol Cell 1 (1998) 619-625
43. Cheng A., Uetani N., Simoncic P.D., et al. Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B. Dev Cell 2 (2002) 497-503
44. Starr R., Willson T.A., Viney E.M., et al. A family of cytokine-inducible inhibitors of signalling. Nature 387 (1997) 917-921
45. Emilsson V., Arch J.R., de Groot R.P., Lister C.A., and Cawthorne M.A. Leptin treatment increases suppressors of cytokine signaling in central and peripheral tissues. FEBS Lett 455 (1999) 170-174
46. Endo T.A., Masuhara M., Yokouchi M., et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387 (1997) 921-924
47. Naka T., Narazaki M., Hirata M., et al. Structure and function of a new STAT-induced STAT inhibitor. Nature 387 (1997) 924-929
48. Zhao A. Is leptin an important physiological regulator of CRP?. Nat Med 13 (2007) 19-21
49. Lammert A., Kiess W., Bottner A., Glasow A., and Kratzsch J. Soluble leptin receptor represents the main leptin binding activity in human blood. Biochem Biophys Res Commun 283 (2001) 982-988
50. Zastrow O., Seidel B., Kiess W., et al. The soluble leptin receptor is crucial for leptin action: evidence from clinical and experimental data. Int J Obes Relat Metab Disord 27 (2003) 1472-1478
51. Pignatti P., Ciapponi L., Galle P., et al. High circulating levels of biologically inactive IL-6/SIL-6 receptor complexes in systemic juvenile idiopathic arthritis: evidence for serum factors interfering with the binding to gp130. Clin Exp Immunol 131 (2003) 355-363
52. Kazumi T., Kawaguchi A., Hirano T., and Yoshino G. C-reactive protein in young, apparently healthy men: associations with serum leptin, QTc interval, and high-density lipoprotein-cholesterol. Metabolism 52 (2003) 1113-1116
53. Shamsuzzaman A.S., Winnicki M., Wolk R., et al. Independent association between plasma leptin and C-reactive protein in healthy humans. Circulation 109 (2004) 2181-2185
54. Mackintosh R.M., and Hirsch J. The effects of leptin administration in non-obese human subjects. Obes Res 9 (2001) 462-469
55. Hukshorn C.J., Lindeman J.H., Toet K.H., et al. Leptin and the proinflammatory state associated with human obesity. J Clin Endocrinol Metab 89 (2004) 1773-1778
56. Hukshorn C.J., van Dielen F.M., Buurman W.A., Westerterp-Plantenga M.S., Campfield L.A., and Saris W.H. The effect of pegylated recombinant human leptin (PEG-OB) on weight loss and inflammatory status in obese subjects. Int J Obes Relat Metab Disord 26 (2002) 504-509
57. Farooqi I.S., and O'Rahilly S. Is leptin an important physiological regulator of CRP?. Nat Med 13 (2007) 16-17
58. Hutchinson W.L., Coll A.P., Gallimore J.R., Tennent G.A., and Pepys M.B. Is leptin an important physiological regulator of CRP?. Nat Med 13 (2007) 17-18
59. Gertler A., Niv-Spector L., and Reicher S. Is leptin an important physiological regulator of CRP?. Nat Med 13 (2007) 18-19
60. Farooqi I.S., Jebb S.A., Langmack G., et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 341 (1999) 879-884
61. Beltowski J. Leptin and atherosclerosis. Atherosclerosis 189 (2006) 47-60
62. Yen T.T., Allan J.A., Pearson D.V., and Schinitsky M.R. Dissociation of obesity, hypercholesterolemia and diabetes from atherosclerosis in ob/ob mice. Experientia 33 (1977) 995-996
63. Kang S.M., Kwon H.M., Hong B.K., et al. Expression of leptin receptor (Ob-R) in human atherosclerotic lesions: potential role in intimal neovascularization. Yonsei Med J 41 (2000) 68-75
64. Farooqi I.S., Matarese G., Lord G.M., et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 110 (2002) 1093-1103
65. Grunfeld C., Zhao C., Fuller J., et al. Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J Clin Invest 97 (1996) 2152-2157
66. Pearson T.A., Mensah G.A., Alexander R.W., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511
67. Landman R.E., Puder J.J., Xiao E., Freda P.U., Ferin M., and Wardlaw S.L. Endotoxin stimulates leptin in the human and nonhuman primate. J Clin Endocrinol Metab 88 (2003) 1285-1291
68. Bornstein S.R., Licinio J., Tauchnitz R., et al. Plasma leptin levels are increased in survivors of acute sepsis: associated loss of diurnal rhythm, in cortisol and leptin secretion. J Clin Endocrinol Metab 83 (1998) 280-283
69. Lord G.M., Matarese G., Howard J.K., Baker R.J., Bloom S.R., and Lechler R.I. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 394 (1998) 897-901
70. Yamagishi S.I., Edelstein D., Du X.L., Kaneda Y., Guzman M., and Brownlee M. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem 276 (2001) 25096-25100
71. O'Rourke L., Gronning L.M., Yeaman S.J., and Shepherd P.R. Glucose-dependent regulation of cholesterol ester metabolism in macrophages by insulin and leptin. J Biol Chem 277 (2002) 42557-42562
72. Ridker P.M., Rifai N., Stampfer M.J., and Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101 (2000) 1767-1772
73. Ridker P.M., Rifai N., Pfeffer M., Sacks F., Lepage S., and Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 101 (2000) 2149-2153
74. Reilly M.P., Rohatgi A., McMahon K., et al. Plasma cytokines, metabolic syndrome, and atherosclerosis in humans. J Invest Med 55 (2007) 26-35
75. Pai J.K., Pischon T., Ma J., et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 351 (2004) 2599-2610
76. Singh P., Hoffmann M., Wolk R., Shamsuzzaman A.S., and Somers V.K. Leptin induces C-reactive protein expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol 27 (2007) e302-e307
77. Calabro P., Willerson J.T., and Yeh E.T. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 108 (2003) 1930-1932
78. Qasim A., Mehta N., Tadesse M.G., et al. Adipokines, insulin resistance and coronary artery calcification. J Am Coll Cardiol 52 (2008) 231-236
79. Ciccone M., Vettor R., Pannacciulli N., et al. Plasma leptin is independently associated with the intima-media thickness of the common carotid artery. Int J Obes Relat Metab Disord 25 (2001) 805-810
80. Mangge H., Schauenstein K., Stroedter L., Griesl A., Maerz W., and Borkenstein M. Low grade inflammation in juvenile obesity and type 1 diabetes associated with early signs of atherosclerosis. Exp Clin Endocrinol Diabetes 112 (2004) 378-382
81. van den Beld A.W., Bots M.L., Janssen J.A., Pols H.A., Lamberts S.W., and Grobbee D.E. Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol 157 (2003) 25-31
82. Oflaz H., Ozbey N., Mantar F., et al. Determination of endothelial function and early atherosclerotic changes in healthy obese women. Diabetes Nutr Metab 16 (2003) 176-181
83. Soderberg S., Ahren B., Stegmayr B., et al. Leptin is a risk marker for first-ever hemorrhagic stroke in a population-based cohort. Stroke 30 (1999) 328-337
84. Soderberg S., Stegmayr B., Stenlund H., et al. Leptin, but not adiponectin, predicts stroke in males. J Intern Med 256 (2004) 128-136
85. Piatti P., Di Mario C., Monti L.D., et al. Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation 108 (2003) 2074-2081
86. Couillard C., Lamarche B., Mauriege P., et al. Leptinemia is not a risk factor for ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Diabetes Care 21 (1998) 782-786
87. Piemonti L., Calori G., Mercalli A., et al. Fasting plasma leptin, tumor necrosis factor-alpha receptor 2, and monocyte chemoattracting protein 1 concentration in a population of glucose-tolerant and glucose-intolerant women: impact on cardiovascular mortality. Diabetes Care 26 (2003) 2883-2889
88. Ozata M., Ozdemir I.C., and Licinio J. Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J Clin Endocrinol Metab 84 (1999) 3686-3695
89. Yildiz B.O., and Haznedaroglu I.C. Rethinking leptin and insulin action: therapeutic opportunities for diabetes. Int J Biochem Cell Biol 38 (2006) 820-830
90. Ahren B., Larsson H., Wilhelmsson C., Nasman B., and Olsson T. Regulation of circulating leptin in humans. Endocrine 7 (1997) 1-8
91. Havel P.J., Kasim-Karakas S., Mueller W., Johnson P.R., Gingerich R.L., and Stern J.S. Relationship of plasma leptin to plasma insulin and adiposity in normal weight and overweight women: effects of dietary fat content and sustained weight loss. J Clin Endocrinol Metab 81 (1996) 4406-4413
92. Boden G., Chen X., Kolaczynski J.W., and Polansky M. Effects of prolonged hyperinsulinemia on serum leptin in normal human subjects. J Clin Invest 100 (1997) 1107-1113
93. Koopmans S.J., Frolich M., Gribnau E.H., Westendorp R.G., and DeFronzo R.A. Effect of hyperinsulinemia on plasma leptin concentrations and food intake in rats. Am J Physiol 274 (1998) E998-E1001
94. Sonnenberg G.E., Krakower G.R., Hoffmann R.G., Maas D.L., Hennes M.M., and Kissebah A.H. Plasma leptin concentrations during extended fasting and graded glucose infusions: relationships with changes in glucose, insulin, and FFA. J Clin Endocrinol Metab 86 (2001) 4895-4900
95. D'Adamo M., Buongiorno A., Maroccia E., et al. Increased OB gene expression leads to elevated plasma leptin concentrations in patients with chronic primary hyperinsulinemia. Diabetes 47 (1998) 1625-1629
96. Seufert J., Kieffer T.J., Leech C.A., et al. Leptin suppression of insulin secretion and gene expression in human pancreatic islets: implications for the development of adipogenic diabetes mellitus. J Clin Endocrinol Metab 84 (1999) 670-676
97. Kamohara S., Burcelin R., Halaas J.L., Friedman J.M., and Charron M.J. Acute stimulation of glucose metabolism in mice by leptin treatment. Nature 389 (1997) 374-377
98. Wang J.L., Chinookoswong N., Scully S., Qi M., and Shi Z.Q. Differential effects of leptin in regulation of tissue glucose utilization in vivo. Endocrinology 140 (1999) 2117-2124
99. Rossetti L., Massillon D., Barzilai N., et al. Short term effects of leptin on hepatic gluconeogenesis and in vivo insulin action. J Biol Chem 272 (1997) 27758-27763
100. Lee Y., Wang M.Y., Kakuma T., et al. Liporegulation in diet-induced obesity. The antisteatotic role of hyperleptinemia. J Biol Chem 276 (2001) 5629-5635
101. Licinio J., Caglayan S., Ozata M., et al. Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc Natl Acad Sci U S A 101 (2004) 4531-4536
102. Oral E.A., Simha V., Ruiz E., et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 346 (2002) 570-578
103. Ferrante Jr. A.W. Obesity-induced inflammation: a metabolic dialogue in the language of inflammation. J Intern Med 262 (2007) 408-414
104. Liu S., Tinker L., Song Y., et al. A prospective study of inflammatory cytokines and diabetes mellitus in a multiethnic cohort of postmenopausal women. Arch Intern Med 167 (2007) 1676-1685
105. Pradhan A.D., Manson J.E., Rifai N., Buring J.E., and Ridker P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286 (2001) 327-334
106. Han T.S., Sattar N., Williams K., Gonzalez-Villalpando C., Lean M.E., and Haffner S.M. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 25 (2002) 2016-2021
107. Schorr U., Blaschke K., Turan S., Distler A., and Sharma A.M. Relationship between angiotensinogen, leptin and blood pressure levels in young normotensive men. J Hypertens 16 (1998) 1475-1480
108. Hirose H., Saito I., Tsujioka M., Mori M., Kawabe H., and Saruta T. The obese gene product, leptin: possible role in obesity-related hypertension in adolescents. J Hypertens 16 (1998) 2007-2012
109. Agata J., Masuda A., Takada M., et al. High plasma immunoreactive leptin level in essential hypertension. Am J Hypertens 10 (1997) 1171-1174
110. Barba G., Russo O., Siani A., et al. Plasma leptin and blood pressure in men: graded association independent of body mass and fat pattern. Obes Res 11 (2003) 160-166
111. Itoh K., Imai K., Masuda T., et al. Relationship between changes in serum leptin levels and blood pressure after weight loss. Hypertens Res 25 (2002) 881-886
112. Haynes W.G. Role of leptin in obesity-related hypertension. Exp Physiol 90 (2005) 683-688
113. Correia M.L., and Haynes W.G. Obesity-related hypertension: is there a role for selective leptin resistance?. Curr Hypertens Rep 6 (2004) 230-235
114. Beltowski J. Role of leptin in blood pressure regulation and arterial hypertension. J Hypertens 24 (2006) 789-801
115. Mathew B., Patel S.B., Reams G.P., Freeman R.H., Spear R.M., and Villarreal D. Obesity-hypertension: emerging concepts in pathophysiology and treatment. Am J Med Sci 334 (2007) 23-30
116. Mark A.L., Correia M.L., Rahmouni K., and Haynes W.G. Selective leptin resistance: a new concept in leptin physiology with cardiovascular implications. J Hypertens 20 (2002) 1245-1250
117. Correia M.L., Haynes W.G., Rahmouni K., Morgan D.A., Sivitz W.I., and Mark A.L. The concept of selective leptin resistance: evidence from agouti yellow obese mice. Diabetes 51 (2002) 439-442
118. Rahmouni K., Morgan D.A., Morgan G.M., Mark A.L., and Haynes W.G. Role of selective leptin resistance in diet-induced obesity hypertension. Diabetes 54 (2005) 2012-2018
119. Munzberg H., Flier J.S., and Bjorbaek C. Region-specific leptin resistance within the hypothalamus of diet-induced obese mice. Endocrinology 145 (2004) 4880-4889
120. Bodary P.F., Westrick R.J., Wickenheiser K.J., Shen Y., and Eitzman D.T. Effect of leptin on arterial thrombosis following vascular injury in mice. JAMA 287 (2002) 1706-1709
121. Konstantinides S., Schafer K., Koschnick S., and Loskutoff D.J. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest 108 (2001) 1533-1540
122. Nakata M., Yada T., Soejima N., and Maruyama I. Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetes 48 (1999) 426-429
123. Thogersen A.M., Soderberg S., Jansson J.H., et al. Interactions between fibrinolysis, lipoproteins and leptin related to a first myocardial infarction. Eur J Cardiovasc Prev Rehabil 11 (2004) 33-40
124. De Mitrio V., De Pergola G., Vettor R., et al. Plasma plasminogen activator inhibitor-I is associated with plasma leptin irrespective of body mass index, body fat mass, and plasma insulin and metabolic parameters in premenopausal women. Metabolism 48 (1999) 960-964
125. Soderberg S., Olsson T., Eliasson M., Johnson O., and Ahren B. Plasma leptin levels are associated with abnormal fibrinolysis in men and postmenopausal women. J Intern Med 245 (1999) 533-543
126. Chu N.F., Spiegelman D., Hotamisligil G.S., Rifai N., Stampfer M., and Rimm E.B. Plasma insulin, leptin, and soluble TNF receptors levels in relation to obesity-related atherogenic and thrombogenic cardiovascular disease risk factors among men. Atherosclerosis 157 (2001) 495-503
127. Guagnano M.T., Romano M., Falco A., et al. Leptin increase is associated with markers of the hemostatic system in obese healthy women. J Thromb Haemost 1 (2003) 2330-2334
128. Skurk T., van Harmelen V., Lee Y.M., Wirth A., and Hauner H. Relationship between IL-6, leptin and adiponectin and variables of fibrinolysis in overweight and obese hypertensive patients. Horm Metab Res 34 (2002) 659-663
129. Malyszko J., Wolczynski S., Malyszko J., and Mysliwiec M. Leptin correlates with some hemostatic parameters in CAPD patients. Nephron 92 (2002) 721-724
130. Yang R., and Barouch L.A. Leptin signaling and obesity: cardiovascular consequences. Circ Res 101 (2007) 545-559
131. Paolisso G., Tagliamonte M.R., Galderisi M., et al. Plasma leptin level is associated with myocardial wall thickness in hypertensive insulin-resistant men. Hypertension 34 (1999) 1047-1052
132. Ogden C.L., Carroll M.D., Curtin L.R., McDowell M.A., Tabak C.J., and Flegal K.M. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295 (2006) 1549-1555
133. Ukkola O., and Kesaniemi Y.A. Leptin and high-sensitivity C-reactive protein and their interaction in the metabolic syndrome in middle-aged subjects. Metabolism 56 (2007) 1221-1227